Although there was consideration for TGF-β antibodies to halt the progression of CKD, all trials thus far have yielded negative results, potentially due to blocking the circulating latent form of TGF-β1 (Shi et al., 2011) which has known beneficial effects across multiple systems. Here, TGFB1 is linked to chronic kidney disease.